L-NMMA
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-negative Breast Cancer
Conditions
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Trial Timeline
Jan 12, 2023 → Dec 2, 2028
NCT ID
NCT05660083About L-NMMA
L-NMMA is a phase 2 stage product being developed by Novartis for HER2-negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05660083. Target conditions include HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05660083 | Phase 2 | Recruiting |
Competing Products
19 competing products in HER2-negative Breast Cancer